The United States Food and Drug Administration ramped up its “War on Kratom” this week by labeling the natural herb as an opioid, and a group of scientists is stepping up to vouch for kratom’s safety, and to argue that banning it would only lead to more opioid-related deaths.
In a statement, FDA Commissioner Scott Gottlieb warned that there is “even stronger evidence of kratom compounds’ opioid properties.” He claimed that there is evidence of 36 deaths related to kratom, but that “many of the cases received could not be fully assessed because of limited information provided.”
In response, a group of scientists came together to send a letter to the acting administrator of the Drug Enforcement Administration, Robert Patterson; and the counselor to the president who is overseeing the administration’s response to the opioid crisis, Kellyanne Conway.
The letter strongly criticized the FDA’s recommendation to label kratom as a Schedule I drug, which would mean that the government will claim that it has no medicinal value.
“We believe strongly that the current body of credible research on the actual effects of kratom demonstrates that it is not dangerously addictive, nor is it similar to ‘narcotics like opioids’ with respect to ‘addiction’ and ‘death’ as stated by the FDA in its November 14th Kratom Advisory. Equally important, four surveys indicate that kratom is presently serving as a lifeline away from strong, often dangerous opioids for many of the several million Americans who use kratom. A ban on kratom that would be imposed by CSA Scheduling would put them at risk of relapse to opioid use with the potential consequence of overdose death. Similar unintended consequences are to be expected in some who would be forced to use opioids to manage acute or chronic pain.”
The scientists noted that when kratom is consumed in raw plant form, “it does not appear to produce the highly addictive euphoria or lethal respiratory depressing effects of classical opioids.” In fact, they argued that labeling kratom as a Schedule I drug would actually increase the number of opioid-related deaths in the United States.
“It is our collective judgment that placing kratom into Schedule I will potentially increase the number of deaths of Americans caused by opioids because many people who have found kratom to be their lifeline away from strong opioids will be vulnerable to resumption of that opioid use, whether their prior opioid use was for relief of pain or due to opioid addiction,” the scientists wrote.
The letter cited several national surveys and a wealth of studies from both the U.S. and Asia, which found that “kratom has been used as a safer alternative to opioids for more than a century,” and if the government truly cared about the safety of the consumer, they would refrain from making kratom a Schedule I drug.
Although the FDA is claiming that kratom is responsible for at least 44 deaths, that is nothing when compared to the number of deaths that have occurred from opioid overdoses in recent years. As President Trump noted at his first State of the Union address, “In 2016, we lost 64,000 Americans to drug overdoses: 174 deaths per day. Seven per hour.”
However, the scientists questioned whether the FDA could actually prove that the deaths it cited were related to kratom overdoses. They noted that while opioid overdose deaths result from respiratory depression and death at high doses, the deaths the FDA claims are from kratom overdoses include “a wide variety of apparent causes in people suffering from various diseases and/or taking other substances that also likely contributed to their deaths.”
Why is the FDA pushing to ban kratom when research has shown that not only is it a safer alternative to opioids, but that it actually helps to prevent opioid-overdose deaths?
As The Free Thought Project has reported, by pushing for a ban on kratom, the FDA is ensuring that Big Pharma will have a lifetime of profit, and the commissioner of the FDA is directly responsible:
Before taking over the FDA and using his position to enrich his fellow legal drug dealers, Gottlieb was a member of GlaxoSmithKline’s product investment board. And, as TFTP has previously reported GlaxoSmithKline owns a patent on a kratom alkaloid designed for the very purpose of treating pain, thereby alleviating dependency on opioids. One of Kratom’s alkaloids—Speciofoline—was researched decades ago by Gottlieb’s former employer and its effects have been widely studied and reported on.
It just so happens that a patent was filed for Speciofoline on August 10, 1964. The patent claims the “alkaloid has useful pharmacodynamic activity, particularly analgetic and antitussive activity.” But that’s not all. Other studies—which the FDA says do not exist—have been conducted for the specific task of treating opioid dependency.
Filed under: General Problems
I previously commented about the kratom situation which without i would be dead now. They ban kratom pain meds and weed you can guarantee ill be the first to go.